Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib + T-DM1 in HER2+ Breast Cancer (HER2CLIMB-02)
NCT03975647Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Oct 2019
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in HER2-positive breast cancer comparing Tucatinib + T-DM1 with Placebo + T-DM1 (2 arms). Primary endpoint: Progression-Free Survival at 43 months. Started Oct 2019; status: active, not recruiting.
02
Drugs
tucatinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03975647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03975647.